The evaluation of the predictive power of LRS in the subgroup analysis and comparison of ROCs with other different prediction models. As determined by Pam50, luminal A, luminal B, HER2-enriched, and basal-like subtypes of breast cancer were subjected to subgroup analysis to evaluate the predictive power of LRS in all NAC patients (A). Then, ROCs of the LRS, Oncotype DX, Gene70, and GGI were compared in (B) the discovery and (C) validation datasets. The AUC was also calculated for each curve.